Compare GNTA & CIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GNTA | CIF |
|---|---|---|
| Founded | 2014 | 1988 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 31.1M |
| IPO Year | 2021 | N/A |
| Metric | GNTA | CIF |
|---|---|---|
| Price | $1.40 | $1.71 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 100.3K | 43.9K |
| Earning Date | 03-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.11% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.28 | $1.47 |
| 52 Week High | $10.00 | $1.77 |
| Indicator | GNTA | CIF |
|---|---|---|
| Relative Strength Index (RSI) | 38.16 | 52.21 |
| Support Level | $1.35 | $1.68 |
| Resistance Level | $1.50 | $1.73 |
| Average True Range (ATR) | 0.15 | 0.02 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 23.53 | 66.67 |
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
Mfs Intermediate High Income Fund is a United States based diversified closed-end management investment company. Its investment objective is to seek high current income but may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment grade corporate bonds, government securities and other securities.